Form 4: Syndax Director Huber Granted 24,000 RSUs

Syndax Pharmaceuticals Director Martin H. Huber Jr. received a grant of 24,000 Restricted Stock Units, increasing his beneficial ownership to 103,000 shares.

Summary

• Martin H. Huber Jr., a Director of Syndax Pharmaceuticals Inc. (SNDX), acquired 24,000 shares of Common Stock.
• The acquisition was an award of Restricted Stock Units (RSUs) with a transaction price of $0.
• Following this transaction, Mr. Huber beneficially owns 103,000 shares of Syndax Pharmaceuticals Common Stock.
• The RSUs are scheduled to vest one year from the grant date, which is February 4, 2026.
• Shares underlying the RSUs will not be delivered, transferred, or sold until the earlier of separation from service, death, disability, or a change in control.
• The transaction was made pursuant to a Rule 10b5-1(c) pre-planned contract, instruction, or written plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, as it signifies continued alignment of a director's interests with shareholders through equity compensation, which is a standard corporate governance practice.

Positives

• The grant of Restricted Stock Units to a director aligns management's interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• The transaction was pre-planned under Rule 10b5-1(c), indicating a structured approach to equity compensation.

Future Outlook

The 24,000 Restricted Stock Units granted to Director Martin H. Huber Jr. are expected to vest one year from the grant date of February 4, 2026, subject to continued service and other conditions.

Industry Context

StockSavvy.ai notes that the granting of Restricted Stock Units to directors is a common practice in the biotechnology and pharmaceutical industry, serving as a key component of executive and director compensation packages to incentivize long-term performance and align interests with shareholders.

Comparison to Industry Standards

• Equity compensation, particularly through Restricted Stock Units, is a standard practice for non-employee directors across publicly traded companies, including those in the pharmaceutical sector like Syndax.
• The vesting schedule of one year is typical for such grants, aiming to retain directors and link their compensation to the company's sustained performance.
• Companies such as Pfizer, Merck, and Johnson & Johnson also utilize similar equity-based compensation structures for their board members to foster long-term commitment and shareholder alignment.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director helps align the director's financial interests with those of the shareholders, potentially encouraging decisions that enhance long-term shareholder value.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The Restricted Stock Units will vest one year from the grant date of February 4, 2026.
• The shares underlying the RSUs will be delivered upon vesting or earlier upon separation from service, death, disability, or change in control.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a director, which is a standard compensation practice designed to align interests. It does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in an investment recommendation. Therefore, a 'hold' recommendation is appropriate as this event alone does not alter the existing investment thesis.

Keywords

Syndax Pharmaceuticals, SNDX, Form 4, Insider Transaction, Restricted Stock Units, RSU, Equity Grant, Director Compensation, Beneficial Ownership, Corporate Governance